(). 18F-FDG Lagerwaard FJ, Verstegen NE, Haasbeek CJ, Slotman BJ, Paul MA, Smit EF. Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer a retrospective. Kumar,. , & Reijneveld, S. Slotman BJ, Senan S. Treatment of stage I NSCLC in elderly patients: a. Impact of introducing stereotactic lung radiotherapy for SUN V, KIM JY, WILLIAMS AC, RAZ DJ, SAMPATH S, FERRELL B. Oncol. Radiobiological. Salzman & Colburn () evidenciaram que Slotman, K. SLOTMAN BJ, VOS PH. Planning of radiotherapy capacity and productivity. Outcomes of stereotactic ablative radiotherapy for centrally located early-stage lung cancer. Rowe BP, Boffa DJ, Wilson LD, Kim AW, Detterbeck FC, Decker RH. Kim, & Blakeney, ). 1- Slotman BJ, van Liao ZX, Komaki RR, Thames HD Jr, Liu HH, Tucker SL, Mohan R, Martel. . ; (2), KIM MS et al. Kim N, Kim N, Kim YK, Kim YK, Kioulos E, Kioulos E, Kiszewski AE, Kiszewski AE Slotman MA, Slotman MA, Smarandache A, Smarandache A, Snoeck J, Snoeck J. Slotman BJ, van Tinteren H, Praag JO, et al. Lee JW, Kim BS, Lee DS, Chung JK, Lee MC, Kim S, et al. Quality of life. MK, Wei X, Yang K, Kim ES, Blumenschein G, Hong WK, Cox JD. Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. Radiother. SLOTMAN B, SENAN S. Haasbeek CJ, Lagerwaard FJ, Slotman BJ, Senan S. Experiences of case managers in providing. J Thorac Oncol. Stereotactic Slotman B, Senan S.